Stem Cell & Regenerative Therapies (Emerging)

DGOU 2024 Position

→ Experimental treatments using stem cells (from fat, bone marrow, etc.) to regenerate cartilage. Stem cells are "blank" cells that can become cartilage cells. Exosomes are tiny healing signal packets cells release.

The German Society of Orthopedics and Traumatology considers adipose-derived MSC therapy for OLT experimental [92]:

→ Adipose-derived = from fat tissue; MSC = Mesenchymal Stem Cells (cells that can become cartilage)

• Limited literature to support adipose-derived MSC use in OLT
• Regulatory restrictions vary by country
• More research needed before routine clinical use

Recent Case Studies (2025)

A November 2025 case using heparin-conjugated fibrin hydrogel with MSCs [93]:

→ Hydrogel = gel-like scaffold that holds cells in place; fibrin = natural clotting protein

• VAS decreased from 60 to 40 at 12 months
• AOFAS increased from 69 to 77
• MRI showed progressive cartilage regeneration with near-complete defect filling

Exosome Therapy (Pre-Clinical)

Exosomes are emerging as potential therapy for cartilage repair [94]:

• MSC-derived exosomes promote chondrocyte proliferation
  → Exosomes = tiny particles cells release to communicate; chondrocytes = cartilage cells; proliferation = growth/multiplication
• Anti-inflammatory and pro-regenerative properties
• Injectable hydrogel delivery systems under development (2025)
• Clinical trials in OLT specifically still needed

CBMA (Concentrated Bone Marrow Aspirate)

CBMA is a simpler stem cell approach harvested during surgery [1]:

→ CBMA = liquid from inside your bones (rich in stem cells) concentrated and applied to the defect

• Single-stage procedure (no cell culture needed)
• Often combined with microfracture or scaffolds
• Technique recommended for lesions >1.5 cm² with bone defects <5mm

The whole evidence base was mapped in July 2026 — and it is eleven studies

→ Someone finally counted every human study of cell therapy for this exact condition. The count is eleven, and in nine of them the cells were given during an operation — so you cannot tell whether the cells helped or the surgery did.

A systematic scoping review charted every human clinical study applying cell-based therapy to post-traumatic ankle osteoarthritis or OLT [229]. It covers BMAC, bone marrow-derived cell transplantation, adipose-derived MSCs, stromal vascular fraction, micro-fragmented adipose tissue, and peripheral blood products — effectively everything on this card.

• Eleven clinical studies exist in total, all non-randomised, Level of Evidence III–V
• Nine of the eleven co-administered the cells with a therapeutic operation — marrow stimulation, osteochondral transplantation, an osteotomy, or debridement. The review names this attribution problem, not any efficacy estimate, as its principal finding: in no charted study can the effect of the cells be separated from the effect of the surgery
• Only two studies used a standalone injection. For degenerative post-traumatic ankle osteoarthritis specifically, the standalone-injection evidence is one case report
• Outcomes were generally favourable and adverse events mild and self-limiting, but no study showed histologically confirmed hyaline cartilage regeneration
• No meta-analysis was performed — the authors judged the literature too heterogeneous and too nearly devoid of controlled trials to pool

The review also argues explicitly that ankle osteoarthritis is a different disease from knee osteoarthritis — predominantly post-traumatic, younger and more active patients, arising from focal talar lesions rather than diffuse degeneration — and that knee evidence should not be read across to it.

Even “which cells” is still an open question

→ Clinics sell “stem cells” as though it were one product. It is not — the cells vary by tissue source and by which subpopulation gets selected, and the field has not settled which is best.

A July 2026 animal study injected human fat-pad-derived mesenchymal stromal cells into a rat osteoarthritis model, comparing cells sorted for the marker CD271 — a marker associated with greater regenerative potential — against ordinary unsorted cells [243]. Both cell groups clearly beat saline on cartilage degeneration, inflammatory cytokines, and pain-related neuropeptides. But the CD271-selected cells outperformed unselected cells on one measure at one timepoint only — histology at day 14 — with no difference in the macroscopic cartilage score, the inflammatory markers, or the pain markers. This is a two-week rat study and it is not evidence for or against any human treatment. It earns a line here for one reason: it shows that the field is still arguing about the basic composition of the injection, which sits awkwardly beside marketing that presents a settled product.

Added August 8, 2026 — the knee now has a 24-trial meta-analysis, which mostly measures how far ahead of the ankle it is

A meta-analysis published August 7 pooled 24 randomized trials, 1,389 patients, of MSC therapy for cartilage defects — significant improvements in pain (SMD −1.31), function, and cartilage volume, with adverse events no different from control [406]. Every included trial is knee — the inclusion criteria say so explicitly — so the scoping review's ankle count above (eleven studies, zero randomized) is untouched, and the review's own warning against reading knee evidence across to the ankle applies to this paper in full. Two subgroup findings are still worth a line, because they bear on which cell product anyone should ever accept: autologous cells beat allogeneic (SMD −1.88 vs −0.80), and bone-marrow-derived beat adipose-derived on cartilage volume. Both point toward the same product — the patient's own marrow — that the BMAC-augmentation trials on topic 30 used, and away from the off-the-shelf allogeneic and fat-derived products most heavily marketed to patients.

Status: These therapies remain experimental. There are still no large RCTs for ankle OLT, and as of July 2026 the standalone injection — the form most often marketed directly to patients — rests on two studies in focal repair and a single case report in degenerative post-traumatic ankle OA. This converges with the 2026 international orthobiologics consensus, which found no formulation or preparation method superior to another [216], and with the AAOS ankle osteoarthritis guideline, which found no reliable evidence for stem cell therapy [228]. Three independent methods reaching the same place is the meaningful signal. None of this establishes that cell therapy fails — it establishes that the study capable of showing whether it works has not been done.